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Abstract: Scaffold proteins play pivotal roles in the regulation of signaling pathways, integrating
external and internal stimuli to various cellular outputs. We report the pattern of cellular and
subcellular expression of scaffoldins angiomotin-like 2 (AmotL2), FK506 binding protein 5 (FKBP51)
and IQ motif containing GTPase-activating protein 1 (IQGAP1) in colorectal cancer (CRC) and
metastases in liver resected after oxaliplatin-based chemotherapy (CT). Positive immunostaining for
the three scaffoldins was found in most cells in healthy colon, tumor, healthy liver and metastasized
liver. The patterns of expression of AmotL2, FKBP51 and IQGAP1 show the greatest variability in
immune system cells and neurons and glia cells and the least in blood vessel cells. The simultaneous
subcellular localization in tumor cells and other cell types within the tumor suggest an involvement
of these three scaffoldins in cancer biology, including a role in Epithelial Mesenchymal Transition.
The display in differential localization and quantitative expression of AmotL2, FKBP51, and IQGAP1
could be used as biomarkers for more accurate tumor staging and as potential targets for anti-cancer
therapeutics by blocking or slowing down their interconnecting functions. Tough further research
needs to be done in order to improve these assessments.
Keywords: colorectal cancer; scaffold proteins; AmotL2; FKBP51; IQGAP1; metastasized liver;
FOLFOX; oxaliplatin; pericytes; telocytes
1. Introduction
Scaffold proteins bring together and facilitate macromolecular interactions between multiple
modular partners that are committed to a specific subcellular task, usually forming a stable complex in
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a peculiar subcellular localization. These superstructures integrate functions such as enzymatic
pathways, cell motility, protein sorting, signaling, stabilization, plasma membrane targeting of
membrane proteins, recycling and cell polarity; in fact, they are involved in cell fate, tumorigenesis,
migration, tumor progression and angiogenesis [1–3].
Colorectal cancer (CRC) is the fourth leading cause of cancer-associated mortality, and >95%
of CRCs are adenocarcinomas [4,5]. FOLFOX (FOL—Folinic acid, leucovorin, F—Fluorouracil,
5-FU) or CAPOX (CA—capecitabine)-chemotherapy of CRC includes oxaliplatin (OX) [6] and is
administered in the treatment of metastatic colorectal cancers in the neo-adjuvant, adjuvant and
palliative setting, with an important percentage of unwanted side effects as peripheral neuropathy [7]
and sinusoidal obstruction syndrome [8]. In the search for early markers of oxaliplatin-related toxicity,
we studied the differential transcriptomics in peripheral white cells (PWCs) from patients receiving
oxaliplatin-based chemotherapy (CT) and found 502 genes significantly up- or down-regulated as a
result of CT [9]. Among those genes, some encoding scaffold proteins presented significant changes in
their expression levels.
In our screening [9], after three cycles of oxaliplatin-based CT, the expression levels of the genes
in PWCs varied as follows: AmotL2 3.5 times higher, FKBP51 2.76 times lower and IQGAP1 with no
detected pre-CT expression level to 229.5 relative to actin expression level [9].
AmotL2 (angiomotin-like 2) is a member of the angiomotin protein family responsible for
maintaining cell-cell interactions to keep asymmetrical apical-basal polarity, avoiding endothelial
detachment and promoting vascular tube formation. Human AmotL2 encodes two isoforms of a
molecular mass of 100 and 60 kDa [10]. Most human cancers have an epithelial origin and the
assessment of malignancy is based on the loss of apicalbasal polarity of the epithelial organization
(epithelial mesenchymal transition (EMT)); however, whether this is a cause or consequence of tumor
progression has yet to be established [11]. Loss of polarity, EMT and angiogenesis are crucial in CRC.
The immunophilin protein FKBP51 (FK506 binding protein 5) is a member of the peptidyl-prolyl
isomerases (PPIs) superfamily [12]. This superfamily includes three distinct classes: the FK506-binding
proteins (FKBPs) (e.g., FKBP12, FKBP51, and FKBP52), the CyclosporinA-binding proteins and the
parvulin-like PPIs [13]. PPIs catalyze the cis-trans conversion of peptidylprolyl imide bonds in target
proteins [14]. FKBP51 protein is localized in mitochondria, cytoplasm and nucleus [14–16]; is involved
in the regulation of a variety of signaling pathways; and is considered as a molecular integrant of the
adaptation process [17]. In many different tumors, altered expression levels have been described [18,19].
Through its influence on steroid receptor maturation, and the regulation of PKA [20], NF-κB [21],
Akt [22] and transforming growth factor β (TGFβ) [23] signaling pathways, FKBP51 plays an important
role in tumorigenesis and response to anti-neoplastic therapy [24,25].
IQGAP1 (IQ motif containing GTPase-activating protein 1) is a multidomain protein ubiquitously
expressed and the most versatile of the three here studied [26]. IQGAP1 modulates several cellular
functions, i.e., cell cycle, cell morphology, motility, by linking elements of the cytoskeleton to cell
adhesion and other signaling molecules [27,28], facilitating the space-time organization and the
coordinated activation of structural and signaling molecules [29,30]. Because of this association with
molecular partners, IQGAP1 accumulates in the plasma membrane at the invasive front in several
cancer types [31–35].
In Figure 1, String analysis [36] shows experimental and databases evidences of known functional
interactions among AmotL2, FKBP51 and IQGAP1 in several physiological and pathological situations
through Yap1, Src and HSP90. The oncogene Src and the chaperone HSP90 are well-known genes
and proteins. In zebrafish embryo, AmotL2 regulates the translocation of phosphorylated Src to
peripheral cell–matrix adhesion sites [37], also required for proper architecture of actin filaments.
Transcriptional coactivator YAP1 (Yes-associated protein 1) (Available online: http://www.uniprot.
org/uniprot/P46937) can act both as a coactivator and a corepressor and is the downstream regulatory
target in the Hippo signaling pathway responsible for organ size control and tumor suppression
by restricting proliferation and promoting apoptosis [38,39]. It also controls cell proliferation in
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response to cell contact, where the TEAD family are required for YAP-dependent gene expression [40].
The TEAD family of transcriptional enhancer factors, also known as TEA domain family, is also required
for YAP-induced cell growth, oncogenic transformation, and epithelial-mesenchymal transition
induction [41]. Some TEAD members are up-regulated in several types of cancer [42].
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Figure 1. String analysis showing interactions among AmotL2, FKBP51 and IQGAP1 proteins. 
FKBP51 (FK506 binding protein 5); HSP90 (heat-shock protein 90); SRC (proto-oncogene tyrosine-
protein kinase); IQGAP1 (IQ-motif containing GTPase-activating protein 1); YAP1 (yes associated 
protein); AmotL2 (angiomotin-like 2). 
Here, we report on the cellular and sub-cellular localization and dynamics of three scaffold 
proteins, AmotL2, FKBP51 and IQGAP1 in colorectal primary tumors and their metastases and in 
apparently healthy areas of metastasized liver. The use of real human tumor samples, with its wide 
heterogeneity of cells, offers a more realistic and more dynamic insight into the onco-biology process 
and is superior to the use of primary cancer cells lines. Primary cancer cell lines studied in monolayer 
culture simply cannot replicate the tumor environment and the intricate complexities of the 
oncogenic process. Based on our findings, the published literature and information available in 
publicly accessible databases, we present a model of interactions between the proteins studied, a 
model that incorporates spatiotemporal interplay between the structural and signaling molecules 
involved in CRC tumorigenesis. 
2. Results 
2.1. AmotL2 in Healthy Colon and in CRC Tissue Samples 
In healthy colon, AmotL2 specific staining of high intensity was observed in blood vessel cells 
(Figure 2A–C; v = vessels) and in stroma cells of the connective tissue surrounding Lieberkühn Crypts 
(LC) (Figure 2A). In the crypts, remarkable immunostaining for AmotL2 was present in epithelial 
cells (nucleus, cytoplasm, and tight junctions) with higher strength in the crypts facing the muscularis 
mucosae (mm) (Figure 2A). Positive AmotL2 labeling was also visible in nuclei of smooth muscle 
cells of the muscularis propria (mp) (Figure 2B) and in cells of submucosal glands (submg) (Figure 
2C). Specific immunostaining for AmotL2 was also present in the cytoplasm of some nerve cell bodies 
of the myenteric plexus (MyP) as well as in some nerve fibers (Figure 2D,D’). 
Figure 1. String analysis showing interactions among AmotL2, FKBP51 and IQGAP1 proteins. FKBP51
(FK506 binding protein 5); HSP90 (heat-shock protei 90); SRC (proto-oncogene tyrosine-protein
kinase); IQGAP1 (IQ-motif containing GTPas -activating protein 1); YAP1 (yes associated p tein);
AmotL2 (a giomotin-like 2).
Here, we report on the cellular and sub-cellular localization and dynamics of three scaffold
proteins, AmotL2, FKBP51 and IQGAP1 in colorectal primary tumors and their metastases and in
apparently healthy areas of metastasized liver. The use of real human tumor samples, with its
wide heterogeneity of cells, offers a more realistic and more dynamic insight into the onco-biology
process and is superior to the use of primary cancer cells lines. Primary cancer cell lines studied in
monolayer culture simply cannot replicate the tumor environment and the intricate complexities of
the oncogenic process. Based on our findings, the published literature and information available in
publicly accessible databases, we present a model of interactions between the proteins studied, a model
that incorporates spatiotemporal interplay between the structural and signaling molecules involved in
CRC tumorigenesis.
2. Results
2.1. AmotL2 in Healthy Colon and in CRC Tissue Samples
In healthy colon, AmotL2 specific staining of high intensity was observed in blood vessel cells
(Figure 2A–C; v = vessels) and in stroma cells of the connec ive tissue urrounding Lieberkühn Crypt
LC) (Figure 2A). In the crypts, remarkab e immun staining for AmotL2 was present in epithelial
cells (nucleus, cytoplasm, and ight junctions) with higher strength in the crypts facing the muscularis
mucosae (mm) (Figure 2A). Pos tive AmotL2 labeling was also visible in nuclei o smoo muscle cell
of the muscularis propria (mp) (F gure 2B) and in cells of submucosal gla ds (submg) (Figure 2C).
Specific immunostaining for AmotL2 was also present in the cytoplasm f some nerve cell bod es of
the my nteric plexus (MyP) as well as in some nerve fibers (Figure 2D,D’).
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Figure 2. Immunolocalization of AmotL2 in: healthy colon (A–D’); and colorectal cancer (CRC) (E–H’); 
Healthy colon: (A) High intensity staining in nucleus, cytoplasm and tight junctions of epithelial cells of 
crypts facing the muscularis mucosae and stromal cells of lamina propria and submucosa; (B) Strong 
AmotL2+ labeling in nuclei of smooth muscle cells of the muscularis propria and in cells of the submucosal 
gland (C); (D,D’) AmotL2+ cytoplasmic expression in nerve cell bodies (thick arrow in D’) of myenteric 
plexus (MyP); some others are negative (thin arrow in D’); Immunopositive nerve fibers. CRC: (E) Faint 
immunostaining in colon epithelial cells and stronger in stromal and immune cells in the connective tissue 
surrounding epithelial crypts and in the submucosa; (F) Tumor tissue infiltrating intestinal epithelium; 
uniform AmotL2 staining in Lieberkühn Crypts. The intensity in the crypts facing the muscularis mucosae 
observed in healthy colon now is much weaker, while tumor cells exhibit a strong immunopositive staining 
in cytoplasm and nuclear membrane, becoming stronger at the invasive front and in budding cells 
(arrows); (G,G’) Magnifications of the boxed areas in (F,G), respectively; (H) Positive staining in neural 
cells of the myenteric plexus, faint in the cytoplasm and stronger in plasma membrane and nucleus (arrow 
in H’); (D’,H’) are magnifications of the boxed areas in (D,H) respectively. Strong AmotL2 immunostaining 
in blood vessel cells, both in healthy and tumor tissues (v). LC = Lieberkühn Crypts; lp = lamina propria; v 
= vessels; mm = muscularis mucosa; sbm = submucosal muscularis; sbmg = submucosal gland; ic = immune 
cells; mp = muscularis propria; icsml = inner circular smooth muscle layer; olsml = outer longitudinal 
smooth muscle layer; T = tumor lesion; MyP = myenteric plexus. 
Figure 2. Immunolocalization of AmotL2 in: healthy colon (A–D’); and colorectal cancer (CRC) (E–H’);
Healthy colon: (A) High intensity staining in nucleus, cytoplasm and tight junctions of epithelial
cells of crypts facing the muscularis mucosae and stromal cells of lamina propria and submucosa;
(B) Strong AmotL2+ labeling in nuclei of smooth muscle cells of the muscularis propria and in cells of
the subm cosal gland (C); (D,D’) AmotL2+ cytoplasmic expressi n in nerve cell bodies (thick arrow in
D’) of myenter c plexus (MyP); som other are nega ive (thin arrow in D’); Immunoposi ve nerve
fiber . CRC: (E) Fa nt immunostaining in colon epithelial cells and stronger i stromal and i mune
cells in the connective tissue surrounding epithelial crypts and in the submucosa; (F) Tumor tissue
infiltrating intestinal epithelium; uniform AmotL2 staining in Lieberkühn Crypts. The intensity in the
crypts facing the muscularis mucosae observed in healthy colon now is much weaker, while tumor
cells exhibit a strong immunopositive staining in cytoplasm and nuclear membrane, becoming stronger
at the invasive front and in budding cells (arrows); (G,G’) Magnifications of the boxed areas in (F,G),
respectively; (H) Positive staining in neural cells of the myenteric plexus, faint in the cytoplasm and
stronger in plasma membrane and nucleus (arrow in H’); (D’,H’) are magnifications of the boxed areas
in (D,H) respectively. Strong AmotL2 immunostaining in blood vessel cells, both in healthy and tumor
tissues (v). LC = Lieb kühn Crypt ; lp = lamina propria; v = vessels; mm = muscularis mucosa; sbm =
submucosal muscularis; sbmg = submucosal gland; ic = immune cells; mp = muscularis propria; icsml
= inner circular smooth muscle layer; olsml = outer longitudinal smooth muscle layer; T = tumor lesion;
MyP = myenteric plexus.
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In unaffected areas of the intestinal epithelium surrounding CRC tissue samples, AmotL2
immunopositive staining was present in Lieberkühn Crypts at a lower intensity compared to healthy
tissue (Figure 2E). Immune cells forming a large inflammation cluster in the submucosa showed strong
labeling (Figure 2, ic = immune cells) as well as cells in the connective tissue surrounding the crypts
and in endothelial cells (Figure 2, v). In tumor affected areas of the intestinal epithelium, Lieberkühn
Crypts exhibited a stronger grade of AmotL2 specific staining (Figure 2F); however, the higher grade
of expression in the crypts facing the muscularis mucosae observed in healthy colon was no longer
visible. Immunostaining was present in tumor cells (cytoplasm and nuclear envelope) at a higher
intensity in budding cells of the invasive front (Figure 2F–G’). Nerve fibers and the cytoplasm of all
nerve cell bodies present in myenteric plexuses in CRC samples showed a fainter staining compared to
what observed in healthy tissue, while plasma membrane and nucleus exhibited a stronger labeling
(Figure 2H,H’).
2.2. AmotL2 in Healthy Liver and in CRC Metastasized Liver Tissue Samples
In healthy liver, the peri-portal hepatocytes, functionally identified as zone 1 where the oxygenated
blood from hepatic arteries enters, exhibited a positive AmotL2 cytoplasmic staining that increased
along the way to the central vein, functionally identified as zone 3, where blood flow is less oxygenated
(Figure S1A–C). This grading of staining was not further observed in apparently healthy areas of
metastasized liver samples (Figure S1E,G). Moreover, in the connective tissue surrounding portal
tracts in healthy liver, except for a few lymphocytes, no significant population of any inflammatory
cell was observed (Figure S1D), while the connective tissue of portal tracts of CRC metastasized liver
tissue appeared highly infiltrated by AmotL2+ immune cells, regardless of the presence or absence
of malignant cells (Figure 3A,A1 and Figure S1H). AmotL2+ immune cells were also present in the
connective tissue surrounding metastasis (Figure 3, asterisks). Metastasis showed high levels of
AmotL2 staining in cytoplasm (Figure 3A–B2); in addition, in malignant budding cells the nuclei were
also positive (Figure 3B2, arrows). In tumor associated blood vessels (v), high levels of AmotL2 specific
labeling were observed in nucleus and cytoplasm of endothelial cells (Figure 3B2,B3).
2.3. AmotL2 in Blood Vessels
In blood vessels of healthy tissues and in tumor associated blood vessels (v), high levels of
AmotL2 specific labeling was observed in nucleus and cytoplasm of endothelial cells (Figure 2, v;
Figure 3C,D, v; Figure 4A–G, white arrows), pericytes (Figure S1D, arrow; Figure 4H–M, white
arrows) and macrophages (Figure 4E–G, yellow arrows; Figure 4H–M, white arrowhead), identified
for their morphology, localization and CD31+ expression (Figure 4E–G, yellow arrows; Figure 4H–M,
arrowhead). Figure 4N–Q shows images of double labeling of AmotL2 and CD31 (Figure 4N,O) or
CD34 (Figure 4P,Q) in serial sections from the same tissue sample, where cells co-expressing the tree
proteins can be observed in perivascular areas (arrows).
2.4. FKBP51
In healthy colon and in apparently healthy areas of CRC tissue sections, an intense positive FKBP51
nuclear staining in enterocytes of intestinal glands and in cells of the lamina propria was observed
(Figure 5A). In CRC tissue sections, FKBP51 protein was localized in the cytoplasm and/or nucleus of
tumor cells as well as in inflammatory and fibrous stromal cells surrounding the lesions (Figure 5B).
Intensity of labeling varies with areas within the section, from a variable positive immunostaining in
tumor cells to no staining detected in others.
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Figure 3. Immunolocalization of AmotL2 in CRC metastasized liver tissue samples. (A,B) Low 
magnification of AmotL2+ staining in: hepatocytes surrounding portal tracts (A); and malignant cells 
(A,B). (A1) Higher magnification of the inset in A; (B1) Higher magnification of the inset 1 in B; 
Asterisks identify AmotL2+ immune cells in the connective tissue surrounding metastasis and portal 
tracts. (B2,B3) Higher magnifications of the insets 2 and 3, respectively, showing the positive AmotL2 
staining in nuclei of malignant budding cells (arrows in B2) and in blood vessel cells (v in B2,B3). pt = 
portal tract; cv = central vein; a = artery; bd = bile duct; M = metastasis; * = clusters of Amotl2+ immune 
cells. 
Figure 3. Im unolocalization of otL2 in CRC etastasized liver tissue samples. (A,B) Low
magnification of AmotL2+ staining in: hepatocytes surrou ding portal tracts (A); and malignant
cells (A,B). (A1) Higher magnificati n of the inset in A; (B1) Higher magnificati n of the inset 1 in B;
Asterisk identify AmotL2+ im une c ll ctive ti sue su rounding metastasis and portal
tracts. (B2,B3) Higher magnificati ts 2 and 3, respectively, showing the positive AmotL2
staini g in uclei of ali ding cells (arrows in B2) and in blood vessel cells (v in B2,B3).
pt = portal tra t; cv = central vein; a = artery; bd = bile duct; M = metastasis; * = clusters of Amotl2+
immune cells.
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Figure 4. Double immunofluorescent staining of AmotL2 protein (green), the pan-macrophage and 
endothelial/pericyte marker CD31 (red) and the endothelial/telocyte marker CD34 in human CRC 
tissue sections. Cellularity is assessed with DAPI. (A–D) Blood cells of tumor associated vessels and 
micro-vessels (arrows) exhibit intense: AmotL2 (A); and CD31 (B) positive staining; both proteins co-
localize along the vessel walls occasionally exhibiting a complementary pattern (C, merge). Arrowhead 
points to a AmotL2+ cell crossing the fenestrated endothelium; (E–G) Positive AmotL2/CD31staining is 
observed in endothelial cells (white arrows) and in macrophage-like cells surrounding the vessels 
(yellow arrows); (H–M) Higher magnifications of the boxed area in G showing the presence of 
AmotL2/CD31 positive pericytes (arrows) surrounding the blood vessel endothelium. Arrowheads 
point to AmotL2+/CD31+ macrophages; (H) AmotL2 (green); (I) CD31 (red); (L) AmotL2/CD31 merged 
images; and (M) AmotL2/CD31/DAPI merged images; (N–Q) Representative images of double labeling 
of: AmotL2 (green) and CD31 (red) (N,O); or AmotL2 (green) and CD34 (red) (P,Q) in serial sections 
from the same tissue sample, where cells co-expressing the AmotL2/CD31/CD34 proteins can be 
observed in perivascular areas (arrows). 
Figure 4. Double immunofluorescent staining of AmotL2 protein (green), the pan-macrophage
and endothelial/pericyte marker CD31 (red) and the endothelial/telocyte marker CD34 in human
CRC tissue sections. Cellularity is assessed with DAPI. (A–D) Blood cells of tumor associated
vessels and micro-vessels (arrows) exhibit intense: AmotL2 (A); and CD31 (B) positive staining;
both proteins co-localize along the vessel walls occasionally exhibiting a complementary pattern
(C, merge). Arrowhead points to a AmotL2+ cell crossing the fenestrated endothelium; (E–G) Positive
AmotL2/CD31staining is observed in endothelial cells (white rrows) and in macro hage-like cells
surrounding the ves els (y llow arrows); (H–M) Higher magnificatio s of the boxed area in G
showing the presence of A otL2/CD31 positive pericytes (arrows) surrounding the blood vessel
endothelium. Arrowheads point to AmotL2+/CD31+ macrophages; (H) AmotL2 (green); (I) CD31
(red); (L) AmotL2/CD31 merged images; and (M) AmotL2/CD31/DAPI merged images; (N–Q)
Representative images of double labeling of: AmotL2 (green) and CD31 (red) (N,O); or AmotL2 (green)
and CD34 (red) (P,Q) in serial sections from the same tissue sample, where cells co-expressing the
AmotL2/CD31/CD34 proteins can be observed in perivascular areas (arrows).
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Figure 5. FKBP51 immunolocalization in paraffin-embedded tissue sections. (A) Staining is present 
in enterocytes (nucleus and cytoplasm) and in cells of the lamina propria in healthy colon and in 
unaffected areas of CRC tissue samples; (B) Variable positive immunostaining in nucleus and 
cytoplasm of CRC. Positive staining in stroma cells surrounding the lesions (sc); (C) Healthy liver; 
and (D) metastasized liver. Variable immunostaining in hepatocytes of both healthy liver and 
pathological tissue, ranging from high (C) to absent. In metastasized liver (D); in areas with high level 
of infiltrating immune cells (iic), cytoplasmic staining of hepatocytes is not detected, while 
immunostaining is localized in the nucleus; (E) In liver metastases, the immunostaining is faint or 
absent. Several stromal and inflammatory cells are FKBP51+. Arrow in (F) points to a FKBP51+ 
fibroblast showing an immature phenotype. Arrows in (G) point to FKBP51+ telocyte-like cells with 
typical triangular cell bodies and 2 to 5 telopodes, interconnected forming a network; (H) CRC tumor 
nest enveloped by several telocyte-like FKBP51+ cells (arrow); (I) Higher magnification of the cells pointed 
in (H); note the connection between telocyte-like cell and tumor nest; (J–L) Immunofluorescent 
colocalization of: FKBP51 (J, green); and CD34 (K, cyan), used as a telocyte marker. (M–P) CRC tissue 
section double immunostained with: FKBP51 (M, green); and PCNA (N, red); (O) FKBP51/CD34 
merge; and (P) FKBP51/CD34/DAPI. 
In healthy liver and in unaffected areas of metastasized liver, some areas showed intense 
immunostaining (Figure 5C) and other well delimited a weak or absent immunostaining for FKBP51. 
Interestingly in high inflammatory infiltration areas of metastasized tissue sections, the cytoplasmic 
staining of hepatocytes was no further observed, while the protein was localized in the nucleus 
(Figure 5D). In metastases, the immunostaining was faint or absent, while in the inflammatory fibrous 
stroma several cells displayed a strong immunostaining (Figure 5E). 
The presence of FKBP51 in tumor and stroma cells has been associated with the immature 
phenotype of stromal fibroblasts and with the EMT phenotype, suggesting a role for this protein in 
the EMT process [16]. Further observations allowed us to identify telocyte-like FKBP51+ cells located 
in close proximity to tumor lesions and often forming networks (Figure 5G–I), characterized by 
Figure 5. FKBP51 immunolocalization in paraffin-embedded tissue sections. (A) Staining is present in
enterocytes (nucleus and cytoplasm) and in cells of the lamina propria in healthy colon and in unaffected
areas of CRC tissue samples; (B) Variable positive immunostaining in nucleus and cytoplasm of CRC.
Positive staining in stroma cells surrounding the lesions (sc); (C) Healthy liver; and (D) metastasized
liver. Variable immunostaining in hepatocytes of both healthy liver and pathological tissue, ranging
from high (C) to absent. In metastasized liver (D); in areas with high level of infiltrating immune
cells (iic), cytoplasmic staining of hepatocytes is not detected, while immunostaining is localized
in the nucleus; (E) In liver metastases, the immunostaining is faint or absent. Several stromal and
inflammatory cells are FKBP51+. Arrow in (F) points to a FKBP51+ fibroblast showing an immature
phenotype. Arrows in (G) point to FKBP51+ telocyte-like cells with typical triangular cell bodies
and 2 to 5 telopodes, interconnected forming a network; (H) CRC tumor nest enveloped by several
telocyte-like FKBP51+ cells (arrow); (I) Higher magnification of the cells pointed in (H); note the
connection between telocyte-like cell and tumor nest; (J–L) Immunofluorescent colocalization of:
FKBP51 (J, green); and CD34 (K, cyan), used as a telocyte marker. (M–P) CRC tissue section double
immunostained with: FKBP51 (M, green); and PCNA (N, red); (O) FKBP51/CD34 merge; and (P)
FKBP51/CD34/DAPI.
In healthy liver and in unaffected areas of metastasized liver, some areas showed intense
immunostaining (Figure 5C) and other well delimited a weak or absent immunostaining for FKBP51.
Interestingly in high inflammatory infiltration areas of metastasized tissue sections, the cytoplasmic
staining of hepatocytes was no further observed, while the protein was localized in the nucleus
(Figure 5D). In metastases, the immunostaining was faint or absent, while in the inflammatory fibrous
stroma several cells displayed a strong immunostaining (Figure 5E).
The presence of FKBP51 in tumor and stroma cells has been associated with the immature
phenotype of stromal fibroblasts and with the EMT phenotype, suggesting a role for this protein
in the EMT process [16]. Further observations allowed us to identify telocyte-like FKBP51+ cells
Int. J. Mol. Sci. 2017, 18, 891 9 of 20
located in close proximity to tumor lesions and often forming networks (Figure 5G–I), characterized
by triangular or spindle body and 2–5 long, slender cytoplasmic telopodes (Figure 5G–L). Double
immunofluorescent experiments using CD34 as a telocyte marker and anti-FKBP51 antibodies showed
co-staining images (Figure 4J–L).
To evaluate a possible role of FKBP51 over the proliferative activity of tumor cells, the proliferation
marker PCNA [43] was used in double immunofluorescence experiments on formalin-fixed,
paraffin-embedded CRC samples. In several malignant cells forming tumor nests, FKBP51 and PCNA
protein exhibited partial colocalization, also a few stromal cells co-expressed both. The distribution of
intranuclear PCNA and FKBP51 surrounding the outer membrane of the nucleus suggests that these
cells were in the early S phase (Figure 5M–P).
2.5. IQGAP1
IQGAP1+ immunostaining was observed in cytoplasm, nuclear envelope, and apical and lateral
membrane of normal epithelial cells (Figure 6A). In tumor lesions, CRC cells exhibited a heterogeneous
staining, with clusters of IQGAP1 negative cells (arrows in Figure 5B) mixed with IQGAP1+ cells where
the protein was localized in cytoplasm, lateral membrane, nuclear envelope and/or nucleus. High
levels of labeling were also observed at the invasive front of the lesion (Figure 6C’). In many lesions,
a strong apical IQGAP1+ immunostaining was present (Figure 6C, arrow). Hepatocytes in healthy
liver and in apparently healthy areas of CRC metastasized liver (Figure 6D,E, respectively) exhibited a
heterogeneous positive IQGAP1 staining in cytoplasm, nuclear envelope and/or nucleus. Assuming
the role of IQGAP1 protein in the regulation of the cytoskeleton functions; double immunofluorescent
experiments were performed to co-localize IQGAP1 and β-tubulin proteins in tissue specimens of
CRC-affected patients (Figure 6F–M). As can be observed in Figure 6F–M, in certain areas of tumor
lesions and metastasis, the co-localization of IQGAP1 and β-tubulin was lost (Figure 6J–M, arrows;
Figure S2A–H).
To further characterize the localization and expression of IQGAP1 protein, we performed double
immunofluorescent staining of IQGAP1 protein and the endothelial/telocyte marker CD34 or the
endothelial/pericyte/macrophage marker CD31. We identified CD34+ telocytes (Figure 6N–Q and
Figure S2I–P) and CD31+ stromal cells co-expressing IQGAP1 (Figure 6R–U, arrows).
Table 1 summarizes expression levels of AmotL2, FKBP51 and IQGAP1 proteins in different cells
of colon and liver from healthy individuals, CRC and metastasized liver after CT. Adjuvant treatment
with FOLFOX-chemotherapy was as follows: Day 1, oxaliplatin 100 mg/m2 intravenous (i.v.) over 2 h
and leucovorin calcium 400 mg/m2 i.v. over 2 h; followed by 5-fluorouracil 400 mg/m2 i.v. bolus and
by 5-fluorouracil 2400 mg/m2 i.v. over 46 h, every 14 days. All patients received the chemotherapy
after the resection of the primary tumor. Thus, the primaries were chemotherapy naïve, while the
liver metastases were chemotherapy-treated. Fifteen (27.8%) patients presented liver metastasis after
CT. Curative resections of liver metastasis were performed followed by adjuvant FOLFOX-CT. The
average age of patients was 59 years old (range 35–78), with 29 (54%) males and 25 (46%) females. Eight
patients (15%) were stage IV and underwent palliative surgery. The other patients, T3–T4, N1–N2 (85%)
were stages partial response upon RECIST (Response Evaluation Criteria In Solid Tumors) criteria.
The survival is 74% (40 patients), with a follow up of six years. Localization of tumors varied from
cecum (4), ascending (13), transverse (8) colon, both flexures (7), sigmoid (16) colon and sigmo-rectal
(3) area and rectum (3).
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Figure 6. (A–E) Immunolocalization of IQGAP1 protein on paraffin-embedded tissue sections;
(A) IQGAP1 staining in cytoplasm, apical and lateral membrane (arrow) and nuclear envelope
(arrowhead) of normal epithelial cells; (B) Heterogeneous staining in tumor lesions, CRC IQGAP1+
cells (cytoplasm, lateral membrane, nuclear envelope and/or nucleus) and clusters of IQGAP1− cells
(arrows). Arrowhead: IQGAP1+ staining in nucleus; (C) CRC tumor lesion with strong apical staining
(arrow in C). (C’) CRC tumor lesion with IQGAP1+ immunostaini g at t invasive fr nt.; (D,E) In
health (D); and met stasized liver (E); heterogeneous I AP1+ staining in hepatocytes is o s rved
(cytoplasm, n cl ar envelope and/or nucleus); (F–M) IQGAP1 (green) and β-tubulin (red) double
immunofluorescent staining in CRC. Variable expression/co-expression of both proteins in a budding
tumor cell cluster (arrow in F–I) and in a tumor lesion (J–M). Arrows in J–M: IQGAP1−/β-tubulin+
CRC tumor cell cluster. (N–Q) Double IQGAP1 (green) and CD34 (endothelial/telocyte marker-red)
on CRC. Arrow points to a CD34+/IQGAP1+ telocyte. (R–U) Co-expression of IQGAP1 (green) and
CD31 (endothelial /macrophage marker-red) in several stromal cells of liver metastasis.
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Table 1. Protein expression levels of AmotL2, FKBP51 and IQGAP1 in different cells of healthy colon
and liver and in CRC and CRC-metastasized liver. − no expression, + faint, ++ medium, +++ high.
Level/level variable level depending on area; ? indeterminate staining.
AmotL2 IQGAP1 FKBP51
Healthy Colon
Epithelial cells (Mucosae) +/+++ +++ +++
Stromal cells (Mucosae) +++ − ++
Immune system cells + ? ++
Blood vessel cells +++ ++ −
Smooth muscle cells +++ ++ +
Neurous (Myenteric plexus) +++ ++ −/+
Glia cells (Myenteric plexus) +++ ++ −/+
Colorectal Cancer
Tumor cells +++ −/+++ −/++
Budding tumor cells +++ −/+++ −/+
Tumor associated stromal cells +++ −/++ −/+++
Epithelial cells (Mucosae) ++ −/+++ ++
Immune system cells +++ +++ +++
Smooth muscle cells ++ − ++
Blood vessel cells +++ +++ −
Neurous (Myenteric plexus) ++ − ++
Glia cells (Myenteric plexus) ++ − ++
Healthy Liver
Hepatocytes +/+++ −/+++ −/++
Epithelial cells (Bile duct) + + −
Blood vessel cells +++ +++ −
Immune system cells − + +
Metastasized Liver
Tumor cells +++ −/++ −/+
Budding tumor cells +++ +++ −
Hepatocytes ++ −/+++ +/++
Epithelial cells (Bile duct) ++ ++ −
Immune system cells +++ +/++ ++
3. Discussion
Cellularity of CRC consists of tumor cells, vascular endothelial cells and inflammatory immune
cells infiltrating apparent normal colon tissue formed by mucosa, glandular, cryptal, submucosa and
muscularis mucosa cells, interstitial cells, endothelial, pericytes and muscular cells of vessels and nerve
cells of myenteric plexuses.
To give better information on CRC tumorigenesis and progression, instead of PCR and Western
blotting methods in whole tumor pieces, for this study, we performed double immunolabeling for light
and confocal microscopy in order to achieve a “cell by cell” analysis to obtain high quality subcellular
localization data of AmotL2, FKBP51, and IQGAP1 proteins.
3.1. AmotL2 Expression in Healthy Colon and in CRC
AmotL2 localizes, virtually, in all kind of cells reported in this study but at different expression
levels. Amot family includes Amot, AmotL1 and AmotL2. Amot is expressed as two different isoforms,
AMOTp80 and AMOTp130 primarily localized to tight junctions [10,44]. As specified in Table 1, most
cells express AmotL2 at variable levels. This fact agrees with the original report by Troyanovsky
et al. [45] in several tissues and cell lines at the mRNA level, and also agrees with expression data
by Microarray, RNAseq and Serial Analysis of Gene Expression (SAGE) reported by the GeneCards
Human Gene Database (Available online: http://www.genecards.org/cgi-bin/carddisp.pl?gene=
AMOTL2). However, little information is available on expression at the protein level. Summary in
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GeneCards indicates the major line of AmotL2 expression at the protein level is blood white cells.
Oxaliplatin-based CT increased AmotL2-mRNA levels in white cells [9].
The over population of pericytes in vascularized areas of CRC drives to think in the possibility that
some of them could come from the EMT evolvement of CRC tumor cells [46]. Most EMT cancer cells
seem to be located in perivascular space and closely associated with blood vessels, thereby simulating
pericytes [46,47]. It has been suggested a reprogramming of carcinoma cells into pericyte-like cells
during EMT essential for tumor vascular stabilization within a new promalignant effect of EMT [46].
From this point of view, AmotL2/CD31 co-expression in pericytes and CRC cell may be indicative of a
common ancestry.
CD34 is selectively expressed on hematopoietic progenitor cells and the small vessel endothelium
of a variety of tissues and telocytes [48,49]. Telocytes are generally defined based on a combination
of peculiar morphology, typical interstitial location, mainly within muscle fibers [48], and expression
of CD34 marker (although there are no strictly telocyte-specific markers). The increased population
of pericytes and telocytes as well as certain population of cells coexpressing AmotL2/CD31/CD34
suggests a pre-commitment stage of cells from which they could take different decisions of final
differentiation [50].
The participation of the angiomotin family isoforms AMOTp80 and AMOTp130 in cancer cell
proliferation has been studied in liver and prostate cancer [51,52]. In liver, Amot-p130 acts as a
tumorigenesis facilitator when associated to Yap cofactor, while, in prostate AMOTp80, not AMOT
p130, functions as a tumor promoter by enhancing PCa cell proliferation. In lung adenocarcinoma,
angiomotin p130 expression correlates with poor prognosis [53].
The variation levels and the subcellular redistribution of AmotL2 shown in this study in tumor
cells, metastasis and blood vessels and adjacent cells are indicative of its involvement in the CRC
tumorigenesis and progression processes.
3.2. AmotL2 Expression in Healthy Colon, Liver and in CRC-Metastasized Liver
Most liver cells types expressed AmotL2. Hepatocytes express AmotL2, apparently, in a gradient
manner, with increasing intensity as a more oxygenated zone is closer (Figure S1A,B). Our images
illustrate how hypoxic gradients may contribute to CRC metastasis implantation and development
in liver and how the gradients of AmotL2 expression in hepatocytes become homogeneous after
being metastasized. If the gradient expression pattern disappears because of FOLFOX-CT, or if the
metastasizing process also affects it, remains to be studied.
The facts that AmotL2 was originally described as a protein responsible for maintaining polarized
endothelial cells attached and involved in vessel formation in angiogenesis and with a role in
tumorigenesis are indicative of the complexity of association as scaffold protein, probably depending
on adaptors that commit AmotL2 to biologically apparently opposite functions. Deregulated AmotL2
expression in tumor and metastasized areas during tumor progression confirms what recently has been
well established in colon cancer tumors, AmotL2 expression correlates with loss of polarity by means of
hypoxia activated c-Fos, leading to loss of tissue architecture [11]. The complex c-Fos/hypoxia-induced
p60 and AmotL2 interacting with the Crb3 and Par3 polarity complexes retain them in large vesicles,
impeding them from reaching the apical membrane [11] and being involved, this way, in EMT.
3.3. FKBP51 Expression in Healthy Colon, Liver, CRC and Metastasized Liver
FKBP51 protein is localized in the nuclei of enterocytes in healthy tissue while in CRC is found
in nuclei and cytoplasm, exhibiting a variable range, from strong to no detectable signal. Metastases
in liver show a faint or absent FKBP51 immunostaining, while the inflammatory fibrous stroma
depicts several cells with a strong immunostaining. This depiction could be related to the effect of
chemotherapy on tumor cells rather than with intrinsic changes of transformation of cells.
The changes of FKBP51 expression in liver tissue surrounding the metastases reported in this
study, could be related with hepatic sinusoidal injury elicited by oxaliplatin therapy [54].
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A role for this protein in EMT has been suggested based on the expression of FKBP51 in tumor
and stromal cells. Indeed, the expression of this immunophilin has been associated to immature
phenotype of the surrounding stromal fibroblasts, increased micro vessel density and tumor associated
macrophages infiltration, suggesting a role in CRC process [19].
FKBP51 and its co-isoform FKBP52 are HSP90 co-chaperones that modify steroid hormone receptor
activity. Figures 6 and 7 illustrate their interaction with the glucocorticoid receptor. The HSP90-FKBP52
complex co-immunoprecipitate with the glucocorticoid (GR) and the mineralocorticoid receptors and
with the dynein–dynactin complex [16,55,56], indicating a retrograde movement of steroid receptors.
FKBP51 is considered a negative regulator of receptor function. The glucocorticoids secretion by some
CRC could be related to this pathway and have immunosuppressive functions cooperating, this way,
to tumor progression [57].
Cytoplasmic FKBP51 is involved in the pro-apoptotic effects of rapamycin: over cell survival and
chemoresistance of cancer cell. Rapamycin inhibits FKBP51 and though hinders NF-κB activation [58].
Mitochondrial-nuclear redistribution of FKBP51 is regulated by the PKA pathway; PKA and FKBP51
mainly colocalize in the nuclear lamina. In the nucleus, FKBP51 is retained by its interaction with the
nuclear matrix and chromatin, regulating expression of target genes [20] (Figure 7, pathway 3).
3.4. IQGAP1 Expression in Healthy Colon, Liver, CRC and Metastasized Liver
The homogeneous distribution of IQGAP1 in normal cells shifts to a broad expression pattern,
ranging from no expression to high level of expression in the whole CRC tumor cell. IQGAP1 seems
to be involved in tumor progression, since its maximum expression is at the growing front of tumor,
just at the apical part of the expanding cells. The absence of IQGAP1 and β-tubulin co-immunostaining
shows groups of tumor cells undergoing EMT.
The interaction of IQGAP1 with cytoplasmic plus-end binding proteins CLIP-170 and APC,
tethering microtubules to the actin network promotes nuclear envelope membrane dynamics [59,60].
Co-localization of IQGAP1, F-actin and β-tubulin proteins at the nuclear envelope has been reported by
Johnson et al. in MCF-7 (breast cancer epithelial cells), HT29 (colon cancer epithelial cells) and NIH3T3
(non-tumor embryonic fibroblasts) cell lines [61]. Those observations suggest a role for IQGAP1 in
cell cycle-associated nuclear envelope assembly/disassembly and in survival, cell growth, cytokinesis,
and cell migration: key processes in tumorigenesis and carcinogenesis [61].
The IQGAP1+ nucleoli, often found throughout the microscopy field, suggests a correlation
between IQGAP1 expression and RNA synthesis in tumor cells, which agrees with the previous
report [62] in mouse oocyte nucleus, forming a ring around the nucleolus only in transcriptionally
active oocytes.
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Figure 7. Model of direct or indirect protein-protein interaction of AmotL2, FKBP51, IQGAP2 and
interacting partners. (PM) Plasma membrane. (NE) Nuclear envelope. AmotL2, as scaffold protein,
may promote translocation and transcriptional activity of YAP. Upon YAP interaction with AmotL2,
YAP shuttles between the cytoplasm and the nucleus. AmotL2 acts as a negative regulator of YAP
by inducing its cytoplasmic retentio or targeting it to cell junctions (1); Within the nucleus, YAP
functions as a transcriptional coactivator of TEAD. The YAP-TEAD complex promotes the transcription
of many genes that encode pro-proliferative and anti-apoptotic proteins. AmotL2 functions as a positive
regulator of YAP by promoting its nuclear translocation (2), where AmotL2 may act as a cofactor for the
transcription of a group of YAP-TEAD target genes (2); Both ways of translocation of FKBP51 between
mitochondrial and nuclear pool. In the nucleus, FKBP51 regulates, presumably blocking, transcription
of GR-target genes, and possibly other targets (3); Cytosolic FKBP51 interacts with glucocorticoid
hormone receptor (GR) and HSP90. Upon binding, the GR heterocomplex exchanges FKBP51 for
FKBP52. FKBP52-GR–chaperone complex is able to interact with dynein and walk by cytoskeletal
tracts through cytosol and, through t e nuclear pore, get into the nucleus, where dissociates and
fa ilitates binding of the steroid-activated receptor to promoter sites (4); In its scaffolding function,
IQGAP1 interacts with the MEK-ERK pathway hyperactivates ERK signaling and promotes tumor cell
proliferation and survival (5). On the other hand, IQGAP1 interaction with the MEK-ERK pathway is
dispensable in normal cell differentiation, growth, and survival [63]. IQGAP1 promotes cell division
and proliferation through IQGAP1-TOR-Akt and suppresses differentiation and apoptosis driving to
transformation [64].
3.5. Final Considerations and Future Research Directions
In this study, we confirm the fundamental role of the cell by cell immunohistochemical analysis
in molecular oncology data interpretation, presenting data compatible with the involvement of
AmotL2, FKBP51 and IQGAP1 proteins in the cellular EMT phenotype. We show evidence that
the scaffoldins show variation in expression and localization at the protein level in tissue samples
of pre-CT treated colorectal adenocarcinoma and in liver metastases from patients that underwent
FOLFOX-CT. The co-localization of CD34 and AmotL2, FKBP51 and IQGAP1 in several vessels is
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indicative of a role for these three scaffoldings in tumor angiogenesis and/or in vascular invasion.
Indeed, Yamaoka-Tojo et al. have recently shown IQGAP1 as a VEGFR2 binding protein in quiescent
endothelial cells, playing an important role in the establishment of VE-cadherin-based cell–cell contacts,
and suggested that IQGAP1 may function as a scaffold linking VEGFR2 to the β-catenin/VE-cadherin
compound at the adherens junctions (AJ) [65].
Several pieces of evidence point to a key role for these proteins in the dynamics of tumor cells
and angiogenesis process, including expression in pericytes and/or telocytes. Variations in cellular
expression here described renders scaffoldins AmotL2, FKBP51 and IQGAP1 an attractive group as
biomarkers for diagnostic staging and as targets for therapy, although further research needs to be
done to confirm and to precise these assessments.
Figure 7 shows a model of interactions of AmotL2, FKBP51, and IQGAP1 made upon integration
of our data with the literature and other data from databanks. Scaffold proteins connect structural and
signaling molecules in the spatiotemporal organization and activation in CRC tumorigenic cells [29,30].
The process takes place in different subcellular localizations and at variable expression levels depending
on the status of the cell within the tumor. Further studies are needed to confirm the possible existence
of the complex FKBP51-HSP90-SRC-YAP-AmotL2-IQGAP.
4. Materials and Methods
4.1. Patients, Tumor Tissue and Controls
The study was approved by the Ethics Committee of La Laguna University (La Laguna, Canary
Islands, Spain) and the Ethical Committee of Nuestra Señora de Candelaria University Hospital
(HUNSC); Santa Cruz de Tenerife, Canary Islands, Spain (No. 198/2008, approved on 16 September
2008). All patients signed an informed consent for diagnosis and research on tissue specimens before
entering in the project. Paraffin-embedded tissue samples from 54 patients, ensuring patient anonymity,
and the corresponding clinical data were obtained from the reference medical areas of HUNSC.
Following the same ethics and consent rules, colon and liver samples were obtained from surgery
partial exeresis pieces after trauma of three control males.
4.2. Antibodies
The following primary antibodies were used: rabbit anti-human polyclonal antibody (PAb)
against IQGAP1 (#ABT186 Millipore Corporation, Temecula, CA, USA) 1:500 for IHC-P, 1:250 for IF;
rabbit pAb against FKBP51 (#ab46002; Abcam, Cambridge, UK) 1.25:100 for IHC-P, 1:50 for IF; rabbit
pAb against AMOTL2 (#LS-C178611; LifeSpan BioSciences, Seattle, WA, USA) 1:100 for IHC-P, 1:50 for
IF; mouse monoclonal antibody clone PC10 against anti-proliferating cell nuclear antigen (anti-PCNA,
#1486 772, Roche Diagnostics GmbH, Mannheim, Germany) 1:100; mouse monoclonal anti-human
cluster of differentiation (CD)31 (ready-to-use; #IR610 Dako, Glostrup, Denmark); mouse monoclonal
anti-human CD34 Class II Clone QBEnd10 (ready-to-use; #IR632, Dako, Glostrup, Denmark A/S);
mouse monoclonal anti-β tubulin (#sc-101527 Santa Cruz Biotechnology, Dallas, TX, USA) 1:150.
Secondary antibodies: fluorescein isothiocyanate (FITC)-conjugated goat pAb against rabbit IgG
(#F9887; Sigma-Aldrich, St. Louis, MO, USA; dilution, 1:200); goat pAb against mouse IgG (DyLight®
650; #ab97018; Abcam, dilution, 1:100); and biotin-conjugated goat pAb against rabbit IgG (H + L)
(#31820; Thermo Fisher Scientific, Inc., Waltham, MA, USA; dilution, 1:300).
4.3. Immunohistochemistry
Samples were fixed in 10% formalin, for 48–72 h at 4 ◦C. Immunoperoxidase staining of
paraffin-embedded tissue sections was performed using the avidin-biotin reaction. Briefly, 5-µm-thick
tissue sections, deparaffinized in xylene and hydrated in graded alcohol baths, were autoclaved
at 120 ◦C for 10 min in sodium citrate buffer (pH 6.0) to uncover hidden antigenic sites (antigen
retrieval). Samples were then incubated for 1 h at room temperature with 5% non-fat dry milk
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in Tris-buffered saline (TBS) to block non-specific sites. The Avidin/Biotin Blocking kit (Vector
Laboratories Inc., Burlingame, CA, USA) was used to block endogenous biotin, according to the
manufacturer‘s instructions. Primary antibodies were applied to slides overnight at 4 ◦C. Endogenous
peroxidase activity was blocked by incubating the slides with 3% hydrogen peroxidase in methanol
for 15 min. Biotin-conjugated anti-rabbit secondary antibody was incubated for 2 h at 37 ◦C, and the
specific antibody staining was amplified with the ABC Peroxidase Staining kit (Thermo Fisher
Scientific, Inc.). 3,3’-diaminobenzidine substrate concentrate (#IHC-101F; Bethyl Laboratories Inc.,
Montgomery, TX, USA) was used to visualize immunohistochemical reactions. Samples incubated
without primary antibodies were used as a negative control. Slides were counterstained with Harris
hematoxylin solution DC (#253949, Panreac Química SLU, Barcelona, Spain) to visualize cell nuclei and
mounted with Eukitt mounting medium (#253681, Panreac Química SLU, Barcelona, Spain). An optical
light microscope (BX50; Olympus Corporation, Tokyo, Japan) was used to visualize the results of
the immunostaining.
4.4. Double Immunofluorescence Simultaneous Staining
Immunofluorescent staining of 10% formalin-fixed paraffin-embedded tissue sections was
performed as previously described [47]. Briefly, 5-µm-thick tissue sections, deparaffinized in xylene
and hydrated in a graded series of alcohol baths, were autoclaved at 120 ◦C for 10 min in sodium citrate
buffer (pH 6.0) to uncover hidden antigenic sites (antigen retrieval). Samples were then incubated
for 1 h at room temperature with 5% bovine serum albumin in Tris-buffered saline (TBS) to block
non-specific sites. Tissue sections were then incubated simultaneously with a mixture of two distinct
primary antibodies overnight at 4 ◦C. Slides were then incubated for 1 h at room temperature in
the dark with a mixture of two secondary antibodies raised in different species and conjugated to
different fluorochromes. Slides were mounted with ProLong® Diamond Anti-fade Mountant with
DAPI (Molecular Probes®; Thermo Fisher Scientific, Inc.) to visualize cell nuclei. Slides were analyzed
using Leica SP8 (Leica Microsystems, Wetzlar, Germany) confocal microscopes and Olympus FV1000
(Olympus Corporation, Tokyo, Japan).
4.5. Image Analysis and Statistical Analysis
To compile tables, two independent observers evaluated the specimens blindly. After an initial
examination of the whole blind-coded material, cut-offs were established by consensus between each
investigator. Staining intensities were graded as strong (+++), moderate (++), weak (+) or absent (−).
When scorings differed by more than one unit, the observers re-evaluated the specimens to reach
consensus, otherwise means of the scorings were calculated.
5. Conclusions
Positive immunostaining for scaffold AmotL2, FKBP51 and IQGAP1 proteins was found in most
cells in healthy colon, tumor, healthy liver and metastasized liver. The expression patterns reveals the
greatest variability in immune system and neural (neurons and glia) cells and the least in blood vessel
cells. The simultaneous subcellular localization of these scaffoldines in tumor cells and other cell types
within the tumor suggest a peculiar involvement in the onco-biology of CRC and metastasis, including
a role in EMT.
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Acknowledgments: This work was supported by grant FIS PI11/00114 to Pablo Martín-Vasallo and grant FIS
PI12/00729, Spain, to Julio Ávila. Supported partially by the Insular Council of Tenerife and grants MCT-FEDER
2003/2004 (Olympus FV-1000) and IMBRAIN-FP7-REGPOT-2012-31637 awarded to the Institute of Biomedical
Technologies and the Center of Biomedical Research of the Canary Islands at Universidad de La Laguna.
Int. J. Mol. Sci. 2017, 18, 891 17 of 20
Author Contributions: Deborah Rotoli, Manuel Morales and Pablo Martín-Vasallo conceived the study and its
design. Manuel Morales, María del Carmen Maeso and María del Pino García selected the patients. Deborah Rotoli,
JulioÁvila, Pablo Martín-Vasallo and Ali Mobasheri drafted and revised the manuscript. María del Carmen Maeso
and María del Pino García selected and handled samples and supervised Histology. Deborah Rotoli carried out
the immunohistochemistry assays, and took and organized the pictures. All authors analyzed and discussed
results and draft versions of the manuscript. All authors read and approved the final manuscript.
Conflicts of Interest: The authors declare no conflict of interest.
Abbreviations
Amot Angiomotin
APC Adenomatous polyposis coli
CLIP-170 Cytoplasmic linker protein CLIP-170
CT Chemotherapy
EMT Epithelial mesenchymal transition
FKBP FK506 binding protein
FOLFOX FOL—Folinic acid, leucovorin, F—Fluorouracil, 5-FU, OX—Oxaliplatin
HSP90 Heat shock protein 90
IQGAP1 IQ-motif containing GTPase activating protein 1
MAPK Mitogen-activated protein kinase
PCNA Proliferating cell nuclear antigen
TEAD Transcriptional enhancer factors
YAP Yes-associated protein
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